Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Haplo-cord HCT
- Development stage
- Phase 2
- Lead developer
- First Affiliated Hospital of Soochow University
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Haplo-cord HCT is a combination hematopoietic cell transplantation procedure that involves the coinfusion of stem cells from both an unrelated umbilical cord blood (UCB) unit and a haploidentical (half-matched) donor, typically a family member. The approach leverages the rapid engraftment potential of CD34-selected cells from the haploidentical donor and the durable engraftment and graft-versus-leukemia effect provided by UCB progenitors. This method is primarily used to treat hematological malignancies such as acute myeloid leukemia (AML), lymphomas, and aplastic anemia in patients lacking fully matched donors. Clinical trials have demonstrated improved overall survival rates compared to standard haplo-HCT alone, with faster neutrophil recovery and enhanced immune reconstitution without excessive adverse events[1][2][3][5]. The mechanism relies on restoring healthy hematopoiesis through allogeneic stem cell infusion while reducing relapse risk via immunologic effects from both graft sources.
- Brand names
- Haplo-cord transplant
- Other names
- haploidentical cord transplantationhaplo-cord transplanthaploidentical hematopoietic cell transplantation with cord bloodhaplo-cord HSCT
Beyond the preview
Go deeper on Haplo-cord HCT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Haplo-cord HCT.